Even as the biotechnology industry remains on track for its best year for initial public offerings since at least 2007, some have begun asking how long the party can last.
Two more Massachusetts biotechs — Acceleron Pharma Inc. and Bind Therapeutics Inc., both based in Cambridge — registered to go public over the past two weeks. That brought to eight the number of biotechnology companies in the state that have completed or filed for IPOs in 2013, and several more have been getting ready to file their papers, industry insiders said.
But with the broader financial markets retreating sharply this month and some market watchers warning the pullback could intensify, the lawyers, accountants, and investment bankers that advise biotech entrepreneurs have been talking about when to take the plunge. Full story for BostonGlobe.com subscribers.